1-20 of 20
Harry Miao
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity

Clinical Trials & Observations
Frederick L. Locke, Tanya Siddiqi, Caron A. Jacobson, Armin Ghobadi, Sairah Ahmed, David B. Miklos, Miguel-Angel Perales, Javier Munoz, Warren B. Fingrut, Martina Pennisi, Jordan Gauthier, Mazyar Shadman, Lohith Gowda, Abu-Sayeef Mirza, Muhammad Bilal Abid, Sanghee Hong, Navneet S. Majhail, Mohamed A. Kharfan-Dabaja, Arushi Khurana, Talha Badar, Yi Lin, N. Nora Bennani, Megan M. Herr, Zhen-Huan Hu, Hai-Lin Wang, Anjani Baer, Elande Baro, Harry Miao, Clare Spooner, Hairong Xu, Marcelo C. Pasquini
Journal: Blood
Blood (2024) 143 (26): 2722–2734.
https://doi.org/10.1182/blood.2023023447
Published: 2024
Includes: Supplemental data
Journal Articles

Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)

Clinical Trials & Observations
Sattva S. Neelapu, Julio C. Chavez, Alison R. Sehgal, Narendranath Epperla, Matthew Ulrickson, Emmanuel Bachy, Pashna N. Munshi, Carla Casulo, David G. Maloney, Sven de Vos, Ran Reshef, Lori A. Leslie, Olalekan O. Oluwole, Ibrahim Yakoub-Agha, Rashmi Khanal, Joseph Rosenblatt, Ronald Korn, Weixin Peng, Christine Lui, Jacob Wulff, Rhine Shen, Soumya Poddar, A. Scott Jung, Harry Miao, Sara Beygi, Caron A. Jacobson
Journal: Blood
Blood (2024) 143 (6): 496–506.
https://doi.org/10.1182/blood.2023021243
Published: 2024
Includes: Supplemental data
Journal Articles

Curative Potential of Axicabtagene Ciloleucel (Axi-Cel): An Exploratory Long-Term Survival Assessment in Patients with Refractory Large B-Cell Lymphoma from ZUMA-1

Sattva S. Neelapu, Caron A. Jacobson, Armin Ghobadi, David B. Miklos, Lazaros J. Lekakis, Clare Spooner, Jenny J. Kim, Harry Miao, Allen Xiaodong Xue, Yan Zheng, Frederick L. Locke
Journal: Blood
Blood (2023) 142 (Supplement 1): 4864.
https://doi.org/10.1182/blood-2023-174288
Published: 2023
Journal Articles

A Retrospective Intra-Patient Analysis from ZUMA-5: Axicabtagene Ciloleucel (Axi-Cel) Compared with Prior Standard-of-Care Therapy in Patients with Relapsed/Refractory Follicular Lymphoma

Emmanuel Bachy, Sattva S. Neelapu, Julio C. Chavez, Ibrahim Yakoub-Agha, Christine Lui, Jacob Wulff, Harry Miao, Olga Nikolajeva, Timothy Best, Camille Linot, Caron A. Jacobson
Journal: Blood
Blood (2023) 142 (Supplement 1): 4865.
https://doi.org/10.1182/blood-2023-175055
Published: 2023
Journal Articles

Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 4-Year Follow-up from the Phase 2 ZUMA-5 Trial

Sattva S. Neelapu, Julio C. Chavez, Alison R Sehgal, Narendranath Epperla, Matthew L. Ulrickson, Emmanuel Bachy, Pashna N. Munshi, Carla Casulo, David G Maloney, Sven de Vos, Ran Reshef, Lori A. Leslie, Olalekan O. Oluwole, Ibrahim Yakoub-Agha, Rashmi Khanal, Joseph D. Rosenblatt, Weixin Peng, Christine Lui, Jacob Wulff, Rhine R. Shen, Soumya Poddar, Andrew Lee, Harry Miao, Olga Nikolajeva, Caron A. Jacobson
Journal: Blood
Blood (2023) 142 (Supplement 1): 4868.
https://doi.org/10.1182/blood-2023-174914
Published: 2023
Journal Articles

Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma

Clinical Trials & Observations
Sattva S. Neelapu, Caron A. Jacobson, Armin Ghobadi, David B. Miklos, Lazaros J. Lekakis, Olalekan O. Oluwole, Yi Lin, Ira Braunschweig, Brian T. Hill, John M. Timmerman, Abhinav Deol, Patrick M. Reagan, Patrick Stiff, Ian W. Flinn, Umar Farooq, Andre H. Goy, Peter A. McSweeney, Javier Munoz, Tanya Siddiqi, Julio C. Chavez, Alex F. Herrera, Nancy L. Bartlett, Adrian A. Bot, Rhine R. Shen, Jinghui Dong, Kanwarjit Singh, Harry Miao, Jenny J. Kim, Yan Zheng, Frederick L. Locke
Journal: Blood
Blood (2023) 141 (19): 2307–2315.
https://doi.org/10.1182/blood.2022018893
Published: 2023
Includes: Supplemental data
Journal Articles

Outcomes of Axicabtagene Ciloleucel in Comparison with Chemoimmunotherapy (CIT) in an Elderly Population for Treatment of Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) after Two or More Lines of Prior Therapy

Matthew A. Lunning, Hai-Lin Wang, Zhen-Huan Hu, Frederick L. Locke, Tanya Siddiqi, Caron A. Jacobson, Sairah Ahmed, David B. Miklos, Yi Lin, Brian T. Hill, Armin Ghobadi, Sattva S. Neelapu, Jason Westin, Harry Miao, Shilpa Shahani, Anik R. Patel, Clare Spooner, Christine Fu, Hairong Xu, Marcelo C Pasquini
Journal: Blood
Blood (2022) 140 (Supplement 1): 1852–1855.
https://doi.org/10.1182/blood-2022-162421
Published: 2022
Journal Articles

Real-World Impact of Time from Leukapheresis to Infusion (Vein-to-Vein Time) in Patients with Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel

Frederick L. Locke, Zhen-Huan Hu, Tanya Siddiqi, Caron A. Jacobson, Sarah Nikiforow, Sairah Ahmed, David B. Miklos, Yi Lin, Matthew A. Lunning, Brian T. Hill, Armin Ghobadi, Harry Miao, Shilpa Shahani, Clare Spooner, Christine Fu, Anik R. Patel, Hairong Xu, Marcelo C Pasquini
Journal: Blood
Blood (2022) 140 (Supplement 1): 7512–7515.
https://doi.org/10.1182/blood-2022-155603
Published: 2022
Journal Articles

Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of ZUMA-1 Cohort 6

Olalekan O. Oluwole, Edouard Forcade, Javier Muñoz, Sophie de Guibert, Julie M. Vose, Nancy L. Bartlett, Yi Lin, Abhinav Deol, Peter A. McSweeney, Andre H. Goy, Marie José Kersten, Caron A. Jacobson, Umar Farooq, Monique C. Minnema, Catherine Thieblemont, John Timmerman, Patrick Stiff, Irit Avivi, Dimitrios Tzachanis, Yan Zheng, Saran Vardhanabhuti, Jenny Nater, Rhine R. Shen, Harry Miao, Jenny Kim, Tom van Meerten
Journal: Blood
Blood (2022) 140 (Supplement 1): 10399–10401.
https://doi.org/10.1182/blood-2022-156117
Published: 2022
Journal Articles

3-Year Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

Sattva S. Neelapu, Julio Chavez, Alison R. Sehgal, Narendranath Epperla, Matthew Ulrickson, Emanuel Bachy, Pashna N. Munshi, Carla Casulo, David G. Maloney, Sven de Vos, Ran Reshef, Lori A. Leslie, Olalekan O. Oluwole, Ibrahim Yakoub-Agha, Rashmi Khanal, Joseph D. Rosenblatt, Jiali Yan, Qinghua Song, Weixin Peng, Christine Lui, Jacob Wulff, Rhine R. Shen, Soumya Poddar, Harry Miao, Sara Beygi, Caron A. Jacobson
Journal: Blood
Blood (2022) 140 (Supplement 1): 10380–10383.
https://doi.org/10.1182/blood-2022-156120
Published: 2022
Journal Articles

Real-World Bridging Therapy (BT) of Patients with Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) Treated with Chimeric Antigen Receptor (CAR) T-Cell Therapy: A Systematic Literature Review (SLR) and Meta-Analysis

Javier Muñoz, Zhen-Huan Hu, Steve Kanters, Eve H. Limbrick-Oldfield, Harry Miao, Clare Spooner, Hairong Xu, Robin Sanderson
Journal: Blood
Blood (2022) 140 (Supplement 1): 4627–4629.
https://doi.org/10.1182/blood-2022-162582
Published: 2022
Journal Articles

The Echelon-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma

Steven M. Horwitz, MD, Owen A. O'Connor, MD, Barbara Pro, MD, Tim Illidge, MD PhD, Swami P. Iyer, MD, Ranjana Advani, MD, Nancy L. Bartlett, MD, Jacob Haaber Christensen, Franck Morschhauser, MD, Eva Domingo-Domenech, MD, Giuseppe Rossi, MD, Won Seog Kim, PhD, Tatyana A. Feldman, MD, Tobias Menne, MD PhD, David Belada, MD PhD, Árpád Illés, MD PhD, Kensei Tobinai, MD, Kunihiro Tsukasaki, MD PhD, Su-Peng Yeh, MD, Andrei R Shustov, MD, Andreas Hüttmann, MD, Kerry J. Savage, BSc, MD MSc, Sam Yuen, MBBS, FRACP, FRCPA, Pier Luigi Zinzani, MD, Harry Miao, MD, Veronica Bunn, PhD, Keenan Fenton, MA, Michelle A. Fanale, MD, Markus Puhlmann, MD, Lorenz Truemper, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 3–5.
https://doi.org/10.1182/blood-2020-134398
Published: 2020
Journal Articles

Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study

Clinical Trials & Observations
David J. Straus, Monika Długosz-Danecka, Sergey Alekseev, Árpád Illés, Marco Picardi, Ewa Lech-Maranda, Tatyana Feldman, Piotr Smolewski, Kerry J. Savage, Nancy L. Bartlett, Jan Walewski, Radhakrishnan Ramchandren, Pier Luigi Zinzani, Martin Hutchings, Joseph M. Connors, John Radford, Javier Munoz, Won Seog Kim, Ranjana Advani, Stephen M. Ansell, Anas Younes, Harry Miao, Rachael Liu, Keenan Fenton, Andres Forero-Torres, Andrea Gallamini
Journal: Blood
Blood (2020) 135 (10): 735–742.
https://doi.org/10.1182/blood.2019003127
Published: 2020
Includes: Supplemental data
Journal Articles

Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study

Nancy L. Bartlett, MD, David J. Straus, MD, Monika Dlugosz-Danecka, MD PhD, Sergey Alekseev, PhD, Arpad Illes, MD, Ewa Lech-Maranda, MD PhD, Tatyana A. Feldman, MD, Piotr Smolewski, MD PhD, Kerry J Savage, BSc, MD MSc, Jan Walewski, MD PhD, Radhakrishnan Ramchandren, MD, Pier Luigi Zinzani, MD PhD, Martin Hutchings, MD PhD, Joseph M. Connors, MD, John Radford, Javier Munoz, MD MS, FACP, Won-Seog Kim, MD PhD, Ranjana H Advani, MD, Stephen M Ansell, MD PhD, Anas Younes, MD, Andrea Gallamini, MD, Harry Miao, MD, Rachael Liu, PhD, Keenan Fenton, Andres Forero-Torres, MD, Marco Picardi, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4026.
https://doi.org/10.1182/blood-2019-124116
Published: 2019
Journal Articles

A Phase 2 Study of TAK-659, an Investigational Reversible Dual SYK/FLT3 Inhibitor, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Tycel J. Phillips, MD, Gilles Salles, MD PhD, Daniel J. Landsburg, MD, Giuseppe Gritti, MD PhD, Krish Patel, MD, Herve Tilly, MD PhD, Catherine Thieblemont, MD PhD, William Townsend, MRCP,MDFRCPath, Silvia Ferrari, MD, Kate F. Stumpo, BA, Shilpi Katyayan, Cheryl Li, Harry Miao, MD, Igor Proscurshim, Ajay K. Gopal, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5310.
https://doi.org/10.1182/blood-2019-125650
Published: 2019
Journal Articles

Brentuximab Vedotin Plus Chemotherapy in Patients with Advanced-Stage Classical Hodgkin Lymphoma (cHL): Evaluation of Modified Progression-Free Survival (mPFS) and Traditional PFS in the Phase 3 ECHELON-1 Study

Joseph M. Connors, MD, Anas Younes, MD, Andrea Gallamini, MD, Stephen M. Ansell, MD PhD, Won-Seog Kim, Ranjana H Advani, MD, Nancy L. Bartlett, MD, David J. Straus, MD, Anna Sureda, MD, Martin Hutchings, MD PhD, Monika Dlugosz-Danecka, MD PhD, Gerald Engley, PharmD, Keenan Fenton, Rachael Liu, PhD, Harry Miao, MD, Hina Jolin, Pharm D, Ashish Gautam, PhD MBA, John Radford, MD FRCP
Journal: Blood
Blood (2018) 132 (Supplement 1): 2904.
https://doi.org/10.1182/blood-2018-99-118828
Published: 2018
Journal Articles

Resolution of Peripheral Neuropathy (PN) in Patients Who Received A+AVD or ABVD in the Phase 3 ECHELON-1 Trial

John Radford, MD FRCP, Joseph M. Connors, MD, Anas Younes, MD, Andrea Gallamini, MD, Stephen M. Ansell, MD PhD, Won Seog Kim, MD PhD, Ajay K. Gopal, MD, Mark S Kaminski, MD, June Won Cheong, MDPhD, Ian W. Flinn, MD PhD, Nagesh Kalakonda, MD, Ruth Pettengell, MD, Monika Dlugosz-Danecka, MD PhD, Gerald Engley, PharmD, Keenan Fenton, Rachael Liu, PhD, Indra Purevjal, Harry Miao, MD, Ashish Gautam, PhD MBA, John Kuruvilla, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2921.
https://doi.org/10.1182/blood-2018-99-111893
Published: 2018
Journal Articles

Older Patients (pts) with Previously Untreated Classical Hodgkin Lymphoma (cHL): A Detailed Analysis from the Phase 3 ECHELON-1 Study

Andrew M. Evens, DO, MSc, Joseph M. Connors, MD, Anas Younes, MD, Stephen M. Ansell, MD PhD, Won Seog Kim, MD PhD, John Radford, MD FRCP, Tatyana A. Feldman, MD, Joseph Tuscano, Kerry J Savage, BSc, MD MSc, Yasuhiro Oki, MD, Andrew P. Grigg, MBBS, FRACP, FRCPA, MD, Christopher Pocock, MD PhD, Monika Dlugosz-Danecka, MD PhD, Keenan Fenton, Gerald Engley, PharmD, Rachael Liu, PhD, Harry Miao, MD, Hina Jolin, Pharm D, Ashish Gautam, PhD MBA, Andrea Gallamini, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1618.
https://doi.org/10.1182/blood-2018-99-112178
Published: 2018
Journal Articles

Discovery of Candidate Predictors of Response to Tazemetostat in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma Using NGS Technology on ctDNA Samples Collected Pre-Treatment

Scott Daigle, Alice A. McDonald, BA, Franck Morschhauser, MD PhD, Gilles Salles, MD, Vincent Ribrag, Pamela McKay, Herve Tilly, Anna Schmitt, John Gerecitano, MD PhD, Christophe Fruchart, MD, Peter Johnson, MD FRCP, John Radford, MD, Michael J. Dickinson, Charles Herbaux, Stephen Opat, FRACP, FRCPA, Wojciech Jurczak, PhDMD, Guillaume Cartron, Thierry Lamy, Pr, MD PhD, Pier Luigi Zinzani, MD, Sarit Assouline, MD, Ryan D. Morin, PhDBSc,MSc, Helen Wu, Mark Sausen, Alicia Clawson, Peter Ho, Harry Miao, Stephen Blakemore
Journal: Blood
Blood (2017) 130 (Supplement 1): 4013.
https://doi.org/10.1182/blood.V130.Suppl_1.4013.4013
Published: 2017
Journal Articles

Response to the EZH2 Inhibitor Tazemetostat Is Independent of Cell of Origin Determined Via Hans Imunohistochemistry or Nanostring Lymphoma Subtyping Test in EZH2 Wild-Type DLBCL Patients

Alice A. McDonald, BA, Franck Morschhauser, MD PhD, Vincent Ribrag, Pamela McKay, Gilles Salles, MD PhD, Herve Tilly, Anna Schmitt, John Gerecitano, MD PhD, Michael J. Dickinson, Sarit Assouline, MD, Corinne Haioun, John G. Gribben, MDDSc FMedSci, Pier Luigi Zinzani, MD, Helen Wu, Steven Kussick, James Storhoff, PhD, John Larus, Alicia Clawson, Adlai Grayson, Scott Daigle, Peter Ho, Harry Miao, Stephen Blakemore
Journal: Blood
Blood (2017) 130 (Supplement 1): 2745.
https://doi.org/10.1182/blood.V130.Suppl_1.2745.2745
Published: 2017